WO2021167497A1 - Генотерапевтический днк-вектор - Google Patents
Генотерапевтический днк-вектор Download PDFInfo
- Publication number
- WO2021167497A1 WO2021167497A1 PCT/RU2021/000073 RU2021000073W WO2021167497A1 WO 2021167497 A1 WO2021167497 A1 WO 2021167497A1 RU 2021000073 W RU2021000073 W RU 2021000073W WO 2021167497 A1 WO2021167497 A1 WO 2021167497A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- dna vector
- gene therapy
- ifna2
- ifna14
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 661
- 238000001415 gene therapy Methods 0.000 title claims abstract description 316
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 446
- 241000282414 Homo sapiens Species 0.000 claims abstract description 118
- 101001034828 Homo sapiens Interferon alpha-14 Proteins 0.000 claims abstract description 95
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 claims abstract description 85
- 101001010600 Homo sapiens Interleukin-12 subunit alpha Proteins 0.000 claims abstract description 85
- 102100040018 Interferon alpha-2 Human genes 0.000 claims abstract description 81
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims abstract description 78
- 102100039733 Interferon alpha-14 Human genes 0.000 claims abstract description 78
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 claims abstract description 78
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 claims abstract description 73
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 claims abstract description 63
- 102100026720 Interferon beta Human genes 0.000 claims abstract description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
- 201000010099 disease Diseases 0.000 claims abstract description 40
- 230000003612 virological effect Effects 0.000 claims abstract description 32
- 239000002671 adjuvant Substances 0.000 claims abstract description 21
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 21
- 210000000987 immune system Anatomy 0.000 claims abstract description 21
- 230000015788 innate immune response Effects 0.000 claims abstract description 21
- 238000002255 vaccination Methods 0.000 claims abstract description 20
- 230000001363 autoimmune Effects 0.000 claims abstract description 19
- 230000000771 oncological effect Effects 0.000 claims abstract description 19
- 210000005260 human cell Anatomy 0.000 claims abstract description 9
- 210000004102 animal cell Anatomy 0.000 claims abstract description 7
- 108020004414 DNA Proteins 0.000 claims description 607
- 230000001225 therapeutic effect Effects 0.000 claims description 219
- 238000001890 transfection Methods 0.000 claims description 113
- 241000588724 Escherichia coli Species 0.000 claims description 111
- 210000004027 cell Anatomy 0.000 claims description 110
- 238000000034 method Methods 0.000 claims description 103
- 108091034117 Oligonucleotide Proteins 0.000 claims description 45
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 45
- 101150110953 IFNA14 gene Proteins 0.000 claims description 42
- 101150043201 IFNA2 gene Proteins 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 34
- 101150011236 IL12A gene Proteins 0.000 claims description 33
- 230000003321 amplification Effects 0.000 claims description 31
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 31
- 101150007193 IFNB1 gene Proteins 0.000 claims description 30
- 230000002068 genetic effect Effects 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 29
- 241001465754 Metazoa Species 0.000 claims description 27
- 238000012408 PCR amplification Methods 0.000 claims description 25
- 238000010839 reverse transcription Methods 0.000 claims description 25
- 230000000259 anti-tumor effect Effects 0.000 claims description 24
- 239000003242 anti bacterial agent Substances 0.000 claims description 23
- 229940088710 antibiotic agent Drugs 0.000 claims description 22
- 230000003115 biocidal effect Effects 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 21
- 230000001771 impaired effect Effects 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 230000004721 adaptive immunity Effects 0.000 claims description 18
- 238000010367 cloning Methods 0.000 claims description 18
- 108091008146 restriction endonucleases Proteins 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 16
- 239000002609 medium Substances 0.000 claims description 15
- 241000282412 Homo Species 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 12
- 230000007017 scission Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 238000004520 electroporation Methods 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 229940041514 candida albicans extract Drugs 0.000 claims description 5
- 229960005091 chloramphenicol Drugs 0.000 claims description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 5
- 238000009776 industrial production Methods 0.000 claims description 5
- 238000011218 seed culture Methods 0.000 claims description 5
- 239000012138 yeast extract Substances 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 239000001888 Peptone Substances 0.000 claims description 4
- 108010080698 Peptones Proteins 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 235000019319 peptone Nutrition 0.000 claims description 4
- 239000006152 selective media Substances 0.000 claims description 4
- 230000005526 G1 to G0 transition Effects 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 108700005077 Viral Genes Proteins 0.000 claims description 2
- 239000013630 prepared media Substances 0.000 claims description 2
- 101150055869 25 gene Proteins 0.000 claims 1
- 101000645421 Homo sapiens Transmembrane protein 165 Proteins 0.000 claims 1
- 102100025755 Transmembrane protein 165 Human genes 0.000 claims 1
- 230000033289 adaptive immune response Effects 0.000 abstract description 2
- 230000000149 penetrating effect Effects 0.000 abstract description 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 85
- 239000002299 complementary DNA Substances 0.000 description 71
- 238000001574 biopsy Methods 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 53
- 210000003527 eukaryotic cell Anatomy 0.000 description 44
- 108020004999 messenger RNA Proteins 0.000 description 39
- 239000000902 placebo Substances 0.000 description 37
- 229940068196 placebo Drugs 0.000 description 37
- 210000002950 fibroblast Anatomy 0.000 description 36
- 238000002347 injection Methods 0.000 description 34
- 239000007924 injection Substances 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 31
- 229940023064 escherichia coli Drugs 0.000 description 30
- 238000004113 cell culture Methods 0.000 description 29
- 238000009825 accumulation Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- 239000000047 product Substances 0.000 description 27
- 108091093088 Amplicon Proteins 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- 101150030333 Il12b gene Proteins 0.000 description 23
- 210000002889 endothelial cell Anatomy 0.000 description 22
- 238000012790 confirmation Methods 0.000 description 20
- 230000005714 functional activity Effects 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 18
- 239000012634 fragment Substances 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 16
- 210000003205 muscle Anatomy 0.000 description 16
- 238000012545 processing Methods 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 101150076800 B2M gene Proteins 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000412 dendrimer Substances 0.000 description 15
- 229920000736 dendritic polymer Polymers 0.000 description 15
- 101100125742 Homo sapiens IFNA2 gene Proteins 0.000 description 14
- 239000013600 plasmid vector Substances 0.000 description 14
- 210000002027 skeletal muscle Anatomy 0.000 description 14
- 210000004683 skeletal myoblast Anatomy 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 210000003606 umbilical vein Anatomy 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 102000013462 Interleukin-12 Human genes 0.000 description 13
- 108010065805 Interleukin-12 Proteins 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 13
- 238000010586 diagram Methods 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 11
- 241000283690 Bos taurus Species 0.000 description 11
- 201000005249 lung adenocarcinoma Diseases 0.000 description 11
- 239000012096 transfection reagent Substances 0.000 description 11
- 108010085238 Actins Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 10
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 210000000981 epithelium Anatomy 0.000 description 10
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 10
- 238000003753 real-time PCR Methods 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 102000007469 Actins Human genes 0.000 description 8
- 101100179429 Homo sapiens IFNB1 gene Proteins 0.000 description 8
- 101100072394 Homo sapiens IL12A gene Proteins 0.000 description 8
- 238000011088 calibration curve Methods 0.000 description 8
- 238000013079 data visualisation Methods 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 101100018679 Homo sapiens IL12B gene Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000001147 pulmonary artery Anatomy 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 102000002227 Interferon Type I Human genes 0.000 description 6
- 108010014726 Interferon Type I Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 210000000245 forearm Anatomy 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 102100036441 Amyloid-beta A4 precursor protein-binding family A member 2 Human genes 0.000 description 5
- 101710093616 Amyloid-beta A4 precursor protein-binding family A member 2 Proteins 0.000 description 5
- 238000008157 ELISA kit Methods 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 101100437218 Homo sapiens B2M gene Proteins 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 5
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960004194 lidocaine Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229940126601 medicinal product Drugs 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000007390 skin biopsy Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 4
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 101150104241 ACT gene Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100028900 Caenorhabditis elegans pcs-1 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108091030084 RNA-OUT Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 102000044762 human IFNA14 Human genes 0.000 description 2
- 102000055062 human IL12A Human genes 0.000 description 2
- 102000050932 human IL12B Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000019734 interleukin-12 production Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 101150025220 sacB gene Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 101150096316 5 gene Proteins 0.000 description 1
- XQMVBICWFFHDNN-UHFFFAOYSA-N 5-amino-4-chloro-2-phenylpyridazin-3-one;(2-ethoxy-3,3-dimethyl-2h-1-benzofuran-5-yl) methanesulfonate Chemical compound O=C1C(Cl)=C(N)C=NN1C1=CC=CC=C1.C1=C(OS(C)(=O)=O)C=C2C(C)(C)C(OCC)OC2=C1 XQMVBICWFFHDNN-UHFFFAOYSA-N 0.000 description 1
- 101100112372 Acinetobacter baylyi (strain ATCC 33305 / BD413 / ADP1) catM gene Proteins 0.000 description 1
- 108090000663 Annexin A1 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 description 1
- 101000583935 Homo sapiens CDK-activating kinase assembly factor MAT1 Proteins 0.000 description 1
- 101000912009 Homo sapiens Cyclin-dependent kinase 5 activator 1 Proteins 0.000 description 1
- 101001038346 Homo sapiens GTP cyclohydrolase 1 feedback regulatory protein Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 1
- 101000980900 Homo sapiens Sororin Proteins 0.000 description 1
- 101000808126 Homo sapiens Uroplakin-3b Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 101150099441 IFNT1 gene Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710106784 Interferon alpha-14 Proteins 0.000 description 1
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010071532 Metastatic choriocarcinoma Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100179435 Mus musculus Ifne gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101100545229 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ZDS2 gene Proteins 0.000 description 1
- 101100113084 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcs2 gene Proteins 0.000 description 1
- 101100022564 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcs4 gene Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 101100167209 Ustilago maydis (strain 521 / FGSC 9021) CHS8 gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 101150053553 catR gene Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 101150028208 hesA gene Proteins 0.000 description 1
- 102000048091 human CDCA5 Human genes 0.000 description 1
- 102000051099 human IFNA2 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011563 immunodeficient animal model Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Definitions
- the invention relates to genetic engineering and can be used in biotechnology, medicine and agriculture to create gene therapy drugs.
- the expression of a gene means the production of a protein molecule with a specific amino acid sequence determined by the nucleotide sequence of this gene.
- cytokines type I interferons
- cytokines exhibit antiviral and antitumor activity and are an important component of innate immunity, and are also involved in cell differentiation.
- Contact with pathogens leads to secretion of interferon I a type that binds to the corresponding receptor complex, which leads to the activation of transcription of genes for chemokines and pro-inflammatory cytokines.
- interferon I a type that binds to the corresponding receptor complex, which leads to the activation of transcription of genes for chemokines and pro-inflammatory cytokines.
- knockout mice for this interferon there is a violation of the maturation of the B cell link of immunity and an increase in susceptibility to viral infection.
- Type I interferons include two groups of proteins, IFN-a and b, which have a variety of immunoregulatory functions that provide a link between innate and adaptive immune responses.
- IFN-a / b The participation of IFN-a / b in the induction of MHC class I expression and activation of NK cells, as well as in the regulation of the expression of other cytokines has been shown.
- type I interferons Based on the data of modern world literature, the following mechanism of action of type I interferons is known: in a controlled viral infection, not strongly expressed and mediated inducers, the functioning of type I interferons is not a systemic, but a local effect.
- IFN-g is produced by CD4 T cells, including when antigens are exposed in the MHC I of CD8 T cells.
- IFNB1 antiviral properties make it possible to control the replication of retroviruses, including HIV.
- HIV infection of mononuclear cells of patients with already expressed IFNB1 gene resulted in suppression of HIV replication in comparison with control cells.
- the transplantation of these cells into mice suppressed HIV replication to a level undetectable by standard methods in 40% of animals (Vieillard V et al., 1999). Similar data were obtained in work on primates (Gay W et al., 2004).
- IFNB1 antitumor activity of IFNB1 was shown experimentally by transfection of human glioma cells with an IFNB1 expression plasmid vector, which resulted in an effective suppression of the proliferative activity of cells in culture (Mizuno M et al., 1990).
- IFNB1 expression plasmid vector which resulted in an effective suppression of the proliferative activity of cells in culture.
- IFNB1 modified cells have also been shown in a mouse model of metastatic choriocarcinoma (Kim GS et al., 2018).
- Other pathologies in which IFNB1 is implicated are autoimmune diseases, with particular emphasis on multiple sclerosis (MS).
- MS multiple sclerosis
- PC IFNB1 therapy is the main one (Rebif, Betaseron, Avonex, etc.).
- the use of gene therapy constructs with the IFNB1 gene seems to be a promising approach in the treatment of MS (Hamana A et al., 2018).
- IFNB1 in nervous tissue also plays a role in the pathogenesis of Parkinson's disease.
- IFNA14, IFNA2 are responsible for the expression of cytokines IFN-a subtypes 14 and 2, also related to type I interferons, which bind to the same type I interferon receptor (IFNAR), while the affinity for it within this group of interferons differs , which is associated with the induction of various signaling pathways.
- IFNAR type I interferon receptor
- IFN-a2 can play the role of the pathogenetically significant subtype itself. Although in this study, only six subtypes of IFN-a were analyzed using the HIV-1 strain implemented in laboratory studies (Sperber SJ et al., 1992). In another study, it was shown that there is an inverse relationship between the expression of IFN-a subtypes and the effectiveness of in vitro suppression of HIV-1 replication. with IFN-ab, -a14 and -a8 (Harper et al., 2015). Plasmid vectors expressing various subtypes of IFN-I demonstrated the longest suppressing HIV replication effect in mice receiving plasmids expressing the IFNB1 and IFNA14 genes (Abraham S et al., 2016).
- each of the subtypes can be used to treat various pathologies of the immune system.
- IL-12 Another cytokine, IL-12, which is pro-inflammatory, is expressed by dendritic cells, macrophages and B cells in response to infectious agents or tumor antigens.
- the genes IL12A, IL12B encode the corresponding subunits - p35 and p40. Its induction stimulates the production of IFN-g by T cells and leads to the potentiation of antigen presentation antigen-presenting cells, stimulating, in turn, the differentiation of TH1 cells. In addition, it can induce the expression of IFN-g in NK cells.
- the clinical manifestation of many infections depends on the ability of the agent to induce IL-12 production. In particular, infection with Candida albicans activates the synthesis of IL-12, which contributes to the further effective protection of cells from the pathogen.
- HIV on the contrary, suppresses the expression of IL-I2, causing numerous disorders of the cellular immune link.
- Leishmanias behave similarly, suppressing the synthesis of IL-12, which contributes to the chronicity of the infection.
- Selective suppression of IL-12 production, while maintaining the expression of other pro-inflammatory cytokines, such as IL-1, TNF-a leads to long-term persistence of pathogens in the host organism (Okwor I, Uzonna JE., 2016).
- the researchers proposed a gene therapy method using IL-12 expressing plasmid vectors to obtain a protective effect against leishmania and trypanosome lesions (Sakai T et al., 2000).
- IL-12-mediated stimulation of TM made it possible to use it as a vaccine in gene therapy constructs for an immunomodulatory effect (Tapia E et al., 2003).
- pathologies such as multiple sclerosis, systemic lupus erythematosus, primary biliary cirrhosis, Behcet's disease, celiac disease, Sjogren's syndrome, mutations associated with the IL12A, IL12B genes have been found.
- the antitumor effect of IL-12 in a gene therapy approach, stimulating dendritic cells and, as a consequence, restoring antitumor immunity has been studied in a number of works (Razi Soofiyani S et al., 2016).
- Denies et al. showed an antitumor effect using a plasmid vector expressing IL-12 in combination with antitumor adjuvant vaccination (Denies S et al., 2014). Due to the fact that the p40 subunit is part of a number of other cytokines from the IL-12 family, modulation of IL12B gene expression using a gene therapy approach offers potential opportunities to influence pathologies associated with insufficient expression of cytokines such as IL-23, IL-27 (Waldner MJ , Neurath MF, 2009).
- the prior art indicates that the genes IFNB1, IFNA14, IFNA2, IL12A, IL12B have the potential to correct a number of abnormalities, including, but not limited to, infectious, autoimmune diseases, cancer, hereditary and acquired pathological conditions, as well as the need modulation of the immune response.
- This is due to the combination of genes IFNB1, IFNA14, IFNA2, IL12A, IL12B within the framework of this patent into a group of genes.
- Genetic constructs providing the expression of proteins encoded by genes from the group IFNB1, IFNA14, IFNA2, IL12A, IL12B can be used for development of drugs for the prevention and treatment of various diseases and pathological conditions.
- these data indicate that insufficient expression of proteins encoded by the IFNB1, IFNA14, IFNA2, IL12A, IL12B genes included in the group of genes is associated not only with pathological conditions, but also with a predisposition to their development. Also, the given data indicate that insufficient expression of these proteins may not manifest itself explicitly in the form of pathology, which can be unambiguously described within the existing standards of clinical practice (for example, using the ICD code), but at the same time cause conditions that are unfavorable for humans and animals and are associated with a deterioration in the quality of life.
- Gene therapy vectors are divided into viral, cellular and DNA vectors (Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal Products EMA / CAT / 801 83/2014). Recently, in gene therapy, more and more attention is paid to the development of non-viral systems for the delivery of genetic material, among which plasmid vectors are in the lead. Plasmid vectors are free from the disadvantages inherent in cellular and viral vectors.
- plasmid vectors for gene therapy are: 1) the presence of antibiotic resistance genes for production in bacterial strains, 2) the presence of various regulatory elements represented by the sequences of viral genomes, 3) the size of the therapeutic plasmid vector, which determines the efficiency of vector penetration into target cell It is known that the European Medicines Agency considers it necessary to avoid the introduction of antibiotic resistance markers into developing plasmid vectors for gene therapy (Reflection paper on design modifications of gene therapy medicinal products during development / 14 December 2011 EMA / CAT / GTWP / 44236/2009 Committee for advanced therapies).
- This recommendation is associated, first of all, with the potential danger of penetration of the DNA vector or horizontal transfer of antibiotic resistance genes into the cells of bacteria present in the body as part of normal or opportunistic microflora.
- the presence of antibiotic resistance genes significantly increases the size of the DNA vector, which leads to a decrease in the efficiency of its penetration into eukaryotic cells.
- antibiotic resistance genes also make a fundamental contribution to the method of obtaining DNA vectors.
- strains for the production of DNA vectors are usually cultivated in a medium containing a selective antibiotic, which creates the risk of the presence of trace amounts of antibiotic in insufficiently purified preparations of DNA vectors.
- obtaining DNA vectors for gene therapy which lack genes for antibiotic resistance, is associated with obtaining strains with such a distinctive feature as the ability to stably amplify target DNA vectors in a medium without antibiotics.
- the European Medical Agency recommends avoiding the presence of regulatory elements in the composition of therapeutic plasmid vectors to increase the expression of target genes (promoters, enhancers, post-translational regulatory elements), which are the nucleotide sequences of the genomes of various viruses (Draft Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products, http://www.ema.europa.eu/docs/en_GB/document_library / Scientific_guideline / 2015/05 / WC500187020.pdf). These sequences, although they can increase the level of expression of the target transgene, however, pose a risk recombination with the genetic material of wild-type viruses and integration into the genome of a eukaryotic cell. Moreover, the feasibility of overexpression of a particular gene for therapy purposes remains an unresolved issue.
- the size of the therapeutic vector is essential. It is known that modern plasmid vectors are often overloaded with non-functional regions that seriously increase the size of the vector (Mairhofer J, Grabherr R. // Mol Biotechnol. Lo 2008.39 (2): 97-104).
- the ampicillin resistance gene in vectors of the pBR322 series as a rule, consists of at least 1000 bp, which is more than 20% of the size of the vector itself.
- an inverse relationship is observed between the size of the vector and its ability to penetrate into eukaryotic cells - DNA vectors with a small size penetrate more effectively into human and animal cells.
- a DNA vector for the sake of safety and maximum efficiency, 25 preference should be given to those constructs that do not contain antibiotic resistance genes, sequences of viral origin and the size of which allows efficient penetration into eukaryotic cells.
- the strain for obtaining such a DNA vector in quantities sufficient for gene therapy purposes must provide the possibility of stable amplification of the DNA vector using nutrient media that do not contain antibiotics.
- the vector is a supercoiled plasmid DNA vector and is intended for the expression of cloned genes in animal and human cells.
- the vector consists of the origin of replication, regulatory elements, including the promoter and enhancer of human cytomegalovirus, regulatory elements from T-15 lymphotropic human virus.
- the accumulation of the vector is carried out in a special strain of E. coli without the use of antibiotics due to antisense complementation of the sacB gene introduced into the strain by means of a bacteriophage.
- the disadvantage of this invention is the presence of regulatory elements in the DNA vector, which are sequences of viral genomes.
- the prototypes of the present invention in terms of the use of gene therapy approaches to increase the level of expression of genes from the group IFNB1, IFNA14, IFNA2, IL12A, IL12B are the following applications.
- US Pat. No. 4,808,523A discloses a plasmid vector carrying a gene encoding IFNB1.
- This vector allows you to increase expression of IFNB1 in mammalian cells.
- the disadvantage of this invention is the method of use, limited to the production of IFNB1 protein in vitro and different from the gene therapy use of this vector. Also, the disadvantage of this invention is the presence in the vector of sequences of viral origin.
- Patent RU2678756 describes a gene therapy DNA vector VTvaf17, a method for its production, an Escherichia coli SCSI 10-AF strain, a method for its production, an Escherichia coli SCSI 10-AF / VTvaf17 strain carrying a gene therapy DNA vector VTvaf17, a method for its production.
- the disadvantage of this invention is the significant size of the vector part, which can negatively affect the efficiency of delivery of the DNA vector into cells.
- US20040203118A1 discloses polynucleotides encoding various IFNA14 variants, as well as a therapeutic agent that is a vector expressing various IFNA14 variants.
- the disadvantage of this invention is the ambiguity of the purposes of using this invention and the uncertain requirements for the safety of the vectors used.
- Application CN101304758A describes a nucleotide sequence encoding IFNA2, as well as a vector expressing this sequence for the treatment of various diseases associated with impaired expression of this gene.
- the disadvantage of this invention is the uncertainty of the safety requirements of the vector used.
- US Pat. No. 5,723,127A describes a method for using IL12 protein for therapeutic immunomodulation, in particular as an adjuvant.
- the disadvantage of this invention is the use of the IL12 protein instead of a gene therapy vector expressing the gene encoding the IL12 protein. Disclosure of invention
- the objective of the invention is to design gene therapy DNA vectors to increase the level of expression of the IFNB1, IFNA14, IFNA2, IL12A, IL12B gene group in humans and animals, combining the following properties:
- the object of the invention is also the design of strains carrying these gene therapy DNA vectors for the development and production on an industrial scale of gene therapy DNA vectors.
- the task is solved due to the fact that a gene therapeutic DNA vector based on the gene therapeutic DNA vector GDTT1.8NAS12 has been created for the treatment of diseases characterized by impaired innate and adaptive immunity, for the therapy of autoimmune, oncological, viral diseases associated with an imbalance of the immune system, for immunomodulation, including during antitumor vaccination as a gene therapeutic adjuvant, while the gene therapeutic DNA vector GDTT1.8NAS12-IFNB1 contains the coding part of the target gene IFNB1, cloned into the gene therapeutic DNA vector
- gene therapy DNA vector GDTT1.8NAS12-IFNA14 contains the coding portion of the target IFNA14 gene cloned into a gene therapy DNA vector
- gene therapy DNA vector GDTT1.8NAS12-IFNA2 contains the coding portion of the target IFNA2 gene cloned into a gene therapy DNA vector
- gene therapy DNA vector GDTT1.8NAS12-IL12A contains the coding portion of the target IL12A gene cloned into the gene therapy DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID N ° 4
- gene therapy DNA -vector GDTT1.8NAS12-IL12B contains the coding part of the target gene IL12B, cloned into a gene therapy DNA vector
- GDTT1.8NAS12 with nucleotide sequence SEQ ID NQ5.
- GDTT 1.8NAS12-IFNB1 As part of each of the created gene therapy DNA vectors: GDTT 1.8NAS12-IFNB1, or GDTT1 .8NAS12-IFNA14, or GDTT1.8NAS12-IFNA2, or GDTT1 .8NAS12-IL12A, or GDTT1.8NAS12-IL12B nucleotide sequences are used as structural elements , which are not genes of antibiotic resistance, viral genes and regulatory elements of viral genomes, ensuring the possibility of its safe use for genetic therapy of humans and animals.
- DNA vectors based on the gene therapy DNA vector GDTT1.8NAS12 carrying the target gene IFNB1, IFNA14, IFNA2, IL12A, IL12B which consists in the fact that each of the gene therapy DNA vectors: GDTT1.8NAS12-IFNB1, or GDTT1.8NAS12-IFNA14 , or GDTT1.8NAS12-IFNA2, or GDTT1.8NAS12-IL12A, or GDTT1.8NAS12-IL12B are obtained as follows: the coding portion of the target gene IFNB1, or IFNA14, or IFNA2, or IL12A, or IL12B is cloned into the gene therapy DNA vector GDTT1.
- TTT GTCG ACT WITH AGTTTCGG AGGT AACCT GT AAGT CTG, and cleavage of the amplification product and cloning of the coding part of the IFNB1 gene into the gene therapeutic DNA vector GDTT1.8NAS12 is carried out using restriction endonucleases BamHI and Sail, and when obtaining gene therapeutic IFNT1 DNA vector GAS14.
- oligonucleotides are used as the oligonucleotides created for this IFNA 14-Fw TTT GG AT CC ACC AT GGC ATT GCCCTTT GCTTT AAT IFNA14-RV TTT GTCGACT C AATCCTTCCTCCTT AAT CTTTTTTGC, and cleavage of the amplification product and cloning of the coding part of the IFNA14 gene into gene therapy with a restriction DNA vector GAS Sail, and when obtaining the gene therapeutic DNA vector GDTT1.8NAS12-IFNA2, SEQID Ns3 for carrying out the reverse transcription reaction and PCR amplification, oligonucleotides IFNA2-FW are used as oligonucleotides created for this IFNA 14-Fw TTT GG AT CC ACC AT GGC ATT GCCCTTT GCTTT AAT IFNA14-RV TTT GTCGACT C AATCCTTCCTCCTT AAT CTTTTTTGC, and cleavage
- cleavage of the amplification product and cloning of the coding part of the IFNA2 gene into the gene therapeutic DNA endon GDTT is carried out using the gene therapeutic DNA endon GDTT.
- oligonucleotides are used as oligonucleotides created for this
- DNA vector GDTT1.8NAS12 is carried out using restriction endonucleases Sail and Kpnl, and when obtaining gene therapeutic DNA vector GDTT1.8NAS12-IL12B, SEQID N ° 5 for carrying out the reaction of reverse transcription and PCR amplification, oligonucleotides IL12B are used as oligonucleotides created for this up
- a method has been created for using a gene therapy DNA vector based on a gene therapeutic DNA vector GDTT1.8NAS12 carrying the target gene IFNB1, IFNA14, IFNA2, IL12A, IL12B for the treatment of diseases characterized by impaired innate and adaptive immunity, for the treatment of autoimmune, oncological, viral diseases associated with with an imbalance of the immune system, for immunomodulation, including during antitumor vaccination as a gene therapeutic adjuvant, which consists in transfection with a selected gene therapeutic DNA vector carrying the target gene based on the gene therapeutic DNA vector GDTT1.8NAS12, or several selected gene therapeutic DNA target vectors carrying genes based gene therapy DNA vector GDTT1.8NAS12, from created gene therapy DNA vectors carrying target genes based on gene therapy DNA vector GDTT1.8NAS12, cells of organs and tissues of a patient or animal, and / or in the introduction into organs and tissues of a patient or animal autologous cells of this patient or animal transfected with the selected gene therapy DNA vector carrying the target gene based on the gene therapy
- systems, for immunomodulation including during antitumor vaccination as a gene therapeutic adjuvant, which consists in obtaining electrocompetent cells of the Escherichia coli JM 110-NAS strain, followed by electroporation of these cells with the gene therapeutic DNA vector GDTT1.8NAS12-IFNB1, or DNAT1 vector GDNB1 -IFNA14, or DNA vector GDTT1.8NAS12- IFNA2, or DNA vector GDTT1.8NAS12-IL12A, or DNA vector GDTT1.8NAS12-IL12B, after which the cells are plated on Petri dishes with agar selective medium containing yeast extract, peptone , 6% sucrose, and 10 ⁇ g / ml chloramphenicol, resulting in Escherichia coli strain JM110-NAS
- NAS / GDTT1.8NAS12-IFNB1 carrying the gene therapeutic DNA vector GDTT1.8NAS12-IFNB1 for its development with the possibility of selection without the use of antibiotics when obtaining a gene therapeutic DNA vector or the Escherichiacoli strain JM110-NAS / GDTT1.8NAS12-IFNA14 carrying DNA -vector GDTT1.8NAS12-IFNA14, for its development with the possibility of selection without the use of antibiotics when obtaining a gene therapeutic DNA vector or the Escherichia coli strain JM110-NAS / GDTT1.8NAS12-IFNA2 carrying a gene therapeutic DNA vector GDTT1.8NAS12- IFNA2, for its production with the possibility of selection without the use of antibiotics when obtaining a gene therapeutic DNA vector, or the Escherichia coli JM1 10-NAS / GDTT1.8NAS12-IL12A strain, carrying the gene therapeutic DNA vector GDTT1.8NAS12-IL12A, for its production with the possibility of selection without the use of antibiotics in the preparation of a gene
- Figure 1 shows a diagram of a gene therapeutic DNA vector GDTT1.8NAS12 carrying a target gene selected from the group of genes IFNB1, IFNA14, IFNA2, IL12A, IL12B, which is a circular double-stranded DNA molecule capable of autonomous replication in Escherichia coli cells.
- Figure 1 shows the diagrams corresponding to:
- EFIa pr is the promoter region of the human elongation factor EF1 A gene with its own enhancer contained in the first intron of the gene. Serves to ensure a high level of transcription of the recombinant gene in most human tissues;
- the target gene reading frame corresponding to the coding portion of the gene IFNB1 (Fig. 1A), or IFNA14 (Fig. 1B), or IFNA2 (Fig. 1C), or IL12A (Fig. 1D) or IL12B (Fig. 1E), respectively; hGH TA - transcription terminator; pUCori - origin of replication, which serves for autonomous replication with a single nucleotide substitution to increase the copy number of the plasmid in the cells of most Escherichia coli strains; RNAout is a regulatory element of the RNA-out transposon Tn 10, which provides the possibility of positive selection without the use of antibiotics when using the Eshcerichia coli JM110NAS strain.
- Figure 2 shows the graphs of the accumulation of cDNA amplicons of the target gene, namely the IFNB1 gene, in the primary culture of human lung fibroblast cells (ATCC PCS-201-020) before their transfection and 48 hours after transfection of these cells with the gene therapeutic DNA vector GDTT1 .8NAS12-IFNB1 to assess the ability to enter eukaryotic cells and functional is activity, that is, the expression of the target gene at the mRNA level.
- the target gene namely the IFNB1 gene
- Figure 2 shows the curves of accumulation of amplicons during the reaction, corresponding to:
- the human B2M gene (Beta-2-microglobulin) listed in the GenBank database under the number NM 004048.2 was used as a reference gene.
- FIG. 3 shows the graphs of the accumulation of cDNA amplicons of the target gene, namely the IFNA14 gene, in the culture of human lung adenocarcinoma cells SK-LU-1 (ATCC ® ⁇ -57 TM ) before their transfection and 48 hours after transfection of these cells with the DNA vector GDTT1.8NAS12 -IFNA14 in order to assess the ability to penetrate into eukaryotic cells and functional activity, that is, the expression of the target gene at the mRNA level.
- the target gene namely the IFNA14 gene
- Fig. 3 shows the accumulation curves of amplicons during the reaction, corresponding to:
- FIG. 4 shows graphs of accumulation of cDNA amplicons of the target gene, namely the IFNA2 gene in human bronchial epithelial cells BZR (ATCC ® CRL-9483 TM ) before their transfection and 48 hours after transfection of these cells with the DNA vector GDTT1.8NAS12-IFNA2 with the purpose of assessing the ability to penetrate into eukaryotic cells and functional activity, that is, the expression of the target gene at the mRNA level.
- Figure 4 shows the accumulation curves of amplicons during the reaction, corresponding to:
- the human B2M gene (Beta-2-microglobulin) listed in the GenBank database under the number NM 004048.2 was used as a reference gene.
- Figure 5 shows the graphs of the accumulation of cDNA amplicons of the target gene, namely the IL12A gene, in the human umbilical vein endothelial cell culture HUVEC (ATCC ® PCS-1 00-010 TM ) before their transfection and 48 hours after transfection of these cells with the DNA vector GDTT1.8NAS12- IL12A in order to assess the ability to penetrate into eukaryotic cells and functional activity, that is, the expression of the target gene at the mRNA level.
- the target gene namely the IL12A gene
- Figure 5 shows the accumulation curves of amplicons in the course of the reaction, corresponding to:
- the human B2M gene (Beta-2-microglobulin) listed in the GenBank database under the number NM 004048.2 was used as a reference gene.
- Fig. 6 shows the graphs of the accumulation of cDNA amplicons of the target gene, namely the IL12B gene, in the cell culture of human skeletal myoblasts HSkM before their transfection and 48 hours after transfection of these cells with the DNA vector GDTT1.8NAS12-IL12B in order to assess the ability to penetrate into eukaryotic cells and functional activity , that is, the expression of the target gene at the mRNA level.
- Figure 6 shows the curves of accumulation of amplicons in the course of the reaction, corresponding to:
- the human B2M gene (Beta-2-microglobulin) listed in the GenBank database under the number NM 004048.2 was used as a reference gene.
- Fig. 7 shows a diagram of the concentration of the IFNB1 protein in the cell lysate of the primary culture of human lung fibroblasts cells (ATCC PCS-201-020) after transfection of these cells with the DNA vector GDTT1.8NAS12-IFNB1 in order to assess the functional activity, that is, expression at the protein level, by changing the amount IFNB1 protein in the cell lysate.
- Figure 7 shows the following elements: culture A - primary culture of human lung fibroblast cells transfected with an aqueous solution of dendrimers without plasmid DNA (control), culture B - primary culture of human lung fibroblast cells transfected with a DNA vector
- GDTT1 .8NAS12 culture C - primary culture of human lung fibroblast cells transfected with a DNA vector
- FIG. 8 shows a diagram of the concentration of IFNA14 protein in the lysate of human lung adenocarcinoma cells SK-LU-1 (ATCC ® TM
- Fig. 8 the following elements are marked: culture A - human lung adenocarcinoma cells SK-LU-1 transfected with an aqueous solution of dendrimers without plasmid DNA (control), culture B - human lung adenocarcinoma cells SK-LU-1 transfected with a DNA vector
- GDTT1.8NAS12 culture C - human lung adenocarcinoma cells SK-LU-1 transfected with a DNA vector
- Figure 9 shows a diagram of the concentration of IFNA2 protein in the lysate of a culture of human bronchial epithelial cells BZR (ATCC ® CRL-9483 TM ) after transfection of these cells with the DNA vector GDTT1.8NAS12-IFNA2 in order to assess the functional activity, that is, the expression of the target gene at the level protein, and the possibility of increasing the level of protein expression using a gene therapeutic DNA vector based on the gene therapeutic DNA vector GDTT1.8NAS12 carrying the target IFNA2 gene.
- Figure 9 shows the following elements: culture A - culture of BZR human bronchial epithelium cells transfected with an aqueous solution of dendrimers without plasmid DNA (control), culture B - culture of human bronchial epithelial cells BZR transfected with the DNA vector GDTT1 .8NAS12, culture C - culture of BZR human bronchial epithelium cells transfected with the DNA vector GDTT1.8NAS12-IFNA2.
- FIG. 10 shows a diagram of the IL12A protein concentration in the lysate of the human umbilical vein endothelial cell culture HUVEC (ATCC ® PCS-100-010 TM ) after transfection of these cells with the DNA vector GDTT1.8NAS12-IL12A in order to assess the functional activity, that is, the expression of the target gene at the level protein, and the possibility of increasing the level of protein expression using a gene therapeutic DNA vector based on the gene therapeutic DNA vector GDTT1.8NAS12 carrying the target IL12A gene.
- Figure 10 shows the following elements: culture A - culture of human umbilical vein endothelial cells HUVEC transfected with an aqueous solution of dendrimers without plasmid DNA (control), culture B - culture of human umbilical vein endothelial cells HUVEC transfected with a DNA vector
- GDTT1.8NAS12 culture C - culture of human umbilical vein endothelial cells HUVEC transfected with the DNA vector GDTT1.8NAS12-IL12A.
- FIG. 11 shows a diagram of the concentration of IL12B protein in the lysate of human skeletal myoblast cell culture HSkM (Gibco, Cat., N ° A12555) after transfection of these cells with the DNA vector GDTT1.8NAS12-IL12B in order to assess the functional activity, that is, the expression of the target gene at the protein level, and the possibility of increasing the level of protein expression using a gene therapeutic DNA vector based on gene therapy DNA vector GDTT1.8NAS12 carrying the target IL12B gene.
- Figure 10 shows the following elements: culture A - cell culture of human skeletal myoblasts HSkM transfected with an aqueous solution of dendrimers without plasmid DNA (control), culture B - culture of cells of human skeletal myoblasts HSkM transfected with the DNA vector GDTT1.8NAS12, culture C - cell culture of human skeletal myoblasts HSkM transfected with the DNA vector GDTT1.8NAS12-IL12B.
- FIG. 12 shows a diagram of the IL12A protein concentration in skin biopsies of three patients after the gene therapy DNA vector was injected into the skin of these patients.
- GDTT1.8NAS12-IL12A in order to assess the functional activity, that is, the expression of the target gene at the protein level, and the possibility of increasing the level of protein expression using a gene therapeutic DNA vector based on the gene therapeutic DNA vector GDTT1.8NAS12 carrying the target gene IL12A.
- the following elements are marked:
- FIG. 13 shows a diagram of the concentration of IFNA2 protein in biopsies of the gastrocnemius muscle of three patients after the introduction of the gene therapy DNA vector GDTT1.8NAS12-IFNA2 into the gastrocnemius muscle of these patients, with the purpose of assessing the functional activity, that is, the expression of the target gene at the protein level, and the possibility of increasing the level of protein expression using a gene therapeutic DNA vector based on the gene therapeutic DNA vector GDTT1.8NAS12 carrying the target IFNA2 gene.
- GDTT1.8NAS12- IFNA2 P3II - biopsy specimen of the gastrocnemius muscle of the patient PZ in the area of injection of gene therapy DNA vector GDTT1.8NAS12 (placebo),
- Fig. 14 shows a diagram of the concentration of IFNA14 protein in skin biopsies of three patients after the introduction of a gene therapy DNA vector into the skin of these patients
- GDTT1.8NAS12-IFNA14 in order to assess the functional activity, that is, the expression of the target gene at the protein level, and the possibility of increasing the level of protein expression using a gene therapy DNA vector based on the is gene therapy DNA vector GDTT1.8NAS12 carrying the target reH-IFNA14.
- FIG. 15 is a diagram of the concentration of IFNA14 protein in human skin biopsies after the introduction into the skin of a culture of autologous fibroblasts transfected with the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 in order to demonstrate the method of application by introducing autologous cells transfected with the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14
- FIG. 16 shows a diagram of the concentrations of proteins: human IFNB1 protein, human IFNA14 protein, human IFNA2 protein, human IL12A protein, human IL12B protein in the muscle tissue of three Wistar rats after injection of a mixture of gene therapy vectors: gene therapy DNA vector GDTT1.8NAS12-IFNB1, gene therapy DNA vector, GDTT1.8NAS12-IFNA14, gene therapy DNA vector, GDTT1.8NAS12-IFNA2, gene therapy DNA vector, GDTT1 .8NAS12-IL12A, gene therapy DNA vector, GDTT1.8NAS12-IL12B to demonstrate the method of application, mixture of gene therapy DNA vectors.
- Fig.16 the following elements are marked:
- K1I - a fragment of K1 rat muscle tissue in the injection zone of a mixture of gene therapy DNA vectors: GDTT1.8NAS12- IFNB1, GDTT1.8NAS12- IFNA14, GDTT1.8NAS12- IFNA2, GDTT1.8NAS12- IL12A and GDTT1.8NAS12- IL12B,
- K1II a fragment of K1 rat muscle tissue in the area of injection of gene therapy DNA vector GDTT1.8NAS12 (placebo), K1 III - a fragment of muscle tissue from the intact control area of the K1 rat,
- K2I - a fragment of K2 rat muscle tissue in the injection zone of a mixture of gene therapy DNA vectors: GDTT1.8NAS12- IFNB1, GDTT1 .8NAS12- IFNA14,
- GDTT1.8NAS12- IFNA2 GDTT1.8NAS12- IL12A and GDTT1.8NAS12- IL12B
- K2II - a fragment of K2 rat muscle tissue in the area of injection of gene therapy DNA vector GDTT1.8NAS12 (placebo),
- K2III - a fragment of muscle tissue from the control intact area of the K2 rat
- K3I - a fragment of the muscle tissue of the KZ rat in the injection zone of a mixture of gene therapy DNA vectors: GDTT1.8NAS12- IFNB1, GDTT1.8NAS12- IFNA14,
- GDTT1.8NAS12- IFNA2 GDTT1.8NAS12- IL12A and GDTT1.8NAS12- IL12B
- K3II - a fragment of the muscle tissue of the KZ rat in the area of injection of gene therapy DNA vector GDTT1.8NAS12 (placebo),
- K3III - a fragment of muscle tissue from the control intact area of the K3 rat.
- FIG. 17 shows the graphs of accumulation of cDNA amplicons of the target IFNA2 gene in bovine pulmonary artery endothelial cells CPAE (ATCC ® CCL-209) before and 48 hours after transfection of these cells with the DNA vector GDTT1.8NAS12-IFNA2 for the purpose of demonstration of the method of application by introducing a gene therapy DNA vector to animals
- Figure 17 shows the accumulation curves of amplicons during the reaction, corresponding to: 1 - cDNA of the IFNA2 gene in the endothelial cells of the pulmonary artery of the bovine CPAE before transfection with the gene therapeutic DNA vector GDTT1.8NAS12-IFNA2,
- bovine / bovine actin (ACT) gene listed in the GenBank database under the number AH001130.2 was used as a reference gene.
- each gene therapy DNA vector carrying the target genes consists in the fact that the polylinker of the gene therapy DNA vectors GDTT1.8NAS12 clone the protein-coding sequence of the target gene selected from the group of genes: IFNB1 gene (encodes IFNB1 protein), IFNA14 gene (encodes IFNA14 protein), IFNA2 gene (encodes IFNA2 protein), IL12A gene (encodes IL12A protein) , human IL12B gene (encodes IL12B protein).
- IFNB1 gene encodes IFNB1 protein
- IFNA14 gene encodes IFNA14 protein
- IFNA2 gene encodes IFNA2 protein
- IL12A gene encodes IL12A protein
- human IL12B gene encodes IL12B protein
- DNA vectors it is known that the ability of DNA vectors to penetrate into eukaryotic cells is mainly determined by the size of the vector. At the same time, DNA vectors with the smallest size have a higher penetrating ability. Thus, it is preferable that the vector contains no elements that do not carry a functional load, but at the same time increase the size of the DNA vector.
- DNA vectors were taken into account when obtaining a gene therapeutic DNA vector based on a gene therapeutic DNA vector GDTT1.8NAS12 carrying a target gene selected from the group of genes IFNB1, IFNA14, IFNA2, IL12A, IL12B due to the absence of large non-functional sequences and genes in the vector antibiotic resistance, which made it possible, in addition to technological advantages and advantages in terms of safety of use, to significantly reduce the size of the obtained gene therapy DNA vector
- GDTT1.8NAS12 carrying a target gene selected from the group of genes IFNB1, IFNA14, IFNA2, IL12A, IL12B.
- DNA vector GDTT 1.8NAS12-IFNB1, or GDTT1.8NAS12-IFNA14, or GDTT1.8NAS12-IFNA2, or GDTT1.8NAS12-IL12A, or GDTT1.8NAS12-IL12B was obtained as follows: gene IFNB1, or IFNA14, or IFNA2, or IL12A, or IL12B was cloned into the gene therapeutic DNA vector GDTT1.8NAS12 and the gene therapeutic DNA vector GDTT1.8NAS12-IFNB1, SEQ ID NQ1, or GDTT1.8NAS12-IFNA14, SEQ ID N ° 2 or GDTT 1.8NAS12-IFNA2, SEQ ID Ne3, or GDTT1.8NAS12-IL12A, SEQ ID No.
- the coding part of the 564 bp IFNB1 gene, or the 570 bp IFNA14 gene, or the 567 bp IFNA2 gene, or the 762 bp IL12A gene, or the 987 bp IL12B gene. was obtained by isolating total RNA from a biological tissue sample of a healthy person. The reverse transcription reaction was used to obtain the first cDNA strand of the human IFNB1, IFNA14, IFNA2, IL12A, IL12B genes. Amplification was carried out using oligonucleotides created for this by the method of chemical synthesis.
- Cleavage of the amplification product with specific restriction endonucleases was carried out taking into account the optimal procedure for further cloning, and cloning into the gene therapeutic DNA vector GDTT1.8NAS12 was performed at the restriction sites BamHI, EcoRI, Hindlll, Kpnl, Sail located in the polylinker of the GDTT1.8NAS12 vector.
- the choice of restriction sites was carried out in such a way that the cloned the fragment fell into frame of reference of the expression cassette of the vector GDTT1.8NAS12, while the protein-coding sequence did not contain restriction sites for the selected endonucleases.
- oligonucleotides can be used to amplify the gene IFNB1, or IFNA14, or IFNA2, or IL12A, or IL12B, various restriction endonucleases, or laboratory techniques such as ligase-free gene cloning.
- Gene therapy DNA vector GDTT1.8NAS12-IFNB1, or GDTT 1.8NAS1 2-IFNA14, or GDTT1.8NAS12-IFNA2, or GDTT1 .8NAS12-IL12A, or GDTT1 .8NAS12-IL12B has the nucleotide sequence SEQ ID Ns1, or SEQ ID Ns1, or SEQ ID Ns1 2, OR SEQ ID Ns3, or SEQ ID N ° 4, or SEQ ID N Q 5, respectively.
- the scope of the present invention also includes variants of nucleotide sequences that differ by insertion, deletion or substitution of nucleotides that are not lead to a change in the polypeptide sequence encoded by the target gene, and / or do not lead to a loss of functional activity of the regulatory elements of the vector GDTT1.8NAS12.
- the scope of the present invention also includes variants of nucleotide sequences of genes from the group of genes IFNB1, IFNA14, IFNA2, IL12A, IL12B, which at the same time encode various variants of amino acid sequences of IFNB1 proteins , IFNA14, IFNA2, IL12A, IL12B do not differ from those given in their functional activity under physiological conditions.
- the ability to penetrate into eukaryotic cells and functional activity that is, the ability to express the target gene of the resulting gene therapeutic DNA vector GDTT1.8NAS12-IFNB1, or GDTT 1.8NAS12-IFNA14, or GDTT1.8NAS12-IFNA2, or GDTT1.8NAS12-IL121, or GDTT1.8NAS12-IL121 .8NAS12-IL12B was confirmed by introducing the resulting vector into eukaryotic cells and then analyzing the expression of the specific mRNA and / or protein product of the target gene.
- GDTT1.8NAS12-IFNB1, or GDTT 1.8NAS12-IFNA14, or GDTT1.8NAS12-IFNA2, or GDTT1.8NAS12-IL12A, or GDTT1.8NAS12-IL12B to express the target gene at the th protein level in eukaryotic cells into which DNA was introduced -vector, the concentration of proteins encoded by the target genes is analyzed using immunological methods.
- the presence of the protein IFNB1, or IFNA14, or IFNA2, or IL12A, or IL12B is confirms the efficiency of expression of target genes in eukaryotic cells and the possibility of increasing the level of protein concentration using a gene therapy DNA vector based on the gene therapy DNA vector GDTT1.8NAS12 carrying the target gene.
- the gene therapeutic DNA vector GDTT1.8NAS12-IFNB1 carrying the target gene namely, the IFNB1 gene
- the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 25 carrying the target gene, namely the IFNA14 gene
- gene therapy DNA - vector GDTT1.8NAS12-IFNA2 carrying the target gene namely, the IFNA2 gene
- gene therapy DNA vector GDTT1.8NAS12-IL12A carrying the target gene, namely the IL12A gene
- the gene therapeutic DNA vector GDTT1.8NAS12-IL12B carrying the target gene namely the IL12B gene
- the gene therapeutic DNA vector GDTT1.8NAS12-IFNB1 carrying the target gene namely the IFNB1 gene
- the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 carrying the target gene, namely the IFNA14 gene
- the gene therapeutic DNA vector GDTT1.8NAS12-IFNA2 carrying the target gene namely the IFNA2 gene
- gene therapy DNA vector GDTT1.8NAS12-IL12A carrying the target gene, namely the IL12A gene
- gene therapeutic DNA vector GDTT1.8NAS12-IL12B carrying the target gene namely the IL12B gene
- antibiotic resistance genes in 5 gene therapy DNA vectors are used to obtain these vectors in preparative quantities by increasing bacterial biomass in a nutrient medium containing a selective antibiotic.
- a gene therapy DNA vector in order to be able to safely use a gene therapy DNA vector
- GDTT1.8NAS12 carrying the target gene IFNB1, or IFNA14, or IFNA2, or IL12A, or IL12B
- the use of selective culture media containing an antibiotic is not possible.
- a technological solution for obtaining a gene therapy DNA vector GDTT1.8NAS12 carrying a target gene selected from the group of genes IFNB1, or IFNA14, or IFNA2, or IL12A, or IL12B for the possibility of scaling up to an industrial scale for obtaining gene therapy vectors it is proposed a method for obtaining strains for the development of the specified gene therapy vectors based on the bacterium Escherichia coli JM110-NAS.
- JM1 10-NAS / GDTT1.8NAS12-IFNB1 or Escherichia coli strain JM110-NAS / GDTT1.8NAS12-IFNA14, or Escherichia coli strain JM1 10-NAS / GDTT 1.8NAS1 2-IFNA2, or Escherichia coli strain JM1 / GD1 .8NAS12-IL12A, 5 or Escherichia coli strain JM110-NAS / GDTT1.8NAS12-IL12B, transformation, selection, and subsequent expansion with isolation of plasmid DNA were carried out.
- gene therapy DNA vector GDTT1.8NAS12-IL12B, carrying the target gene, namely the IL12B gene was fermented on an industrial scale Escherichia coli strain JM110-NAS / GDTT1.8NAS12-IFNB1 or Escherichia coli strain JM110-NAS / GDTT 1.8NAS12-IFNA14 or Escherichia coli strain NAS / JM110-IFNA14 strain GDTT1 NAS
- a method for scaling the production of bacterial mass to an industrial scale for isolation of a gene therapeutic DNA vector GDTT1.8NAS12 carrying a target gene selected from the group of genes IFNB1, IFNA14, IFNA2, IL12A, IL12B consists in the fact that a seed culture of Escherichia coli JM110- NAS / GDTT1.8NAS12-IFNB1, or Escherichia coli strain JM1 10-NAS / GDTT1.8NAS12-IFNA14, or Escherichia coli strain JM1 10-NAS / GDTT1.8NAS12-IFNA2, or Escherichia coli strain JM110T1 / GNAS IL12A, or 5 strains of Escherichia coli JM110-NAS / GDTT1.8NAS12-IL12B are incubated in a volume of culture medium without antibiotic content, providing a suitable dynamics of biomass accumulation, upon reaching a sufficient amount of biomass in the logarithmic growth phase, the bacterial culture is transferred to an industrial ferment
- the cultivation conditions of the strains, the composition of the nutrient media (excluding the content of antibiotics), the equipment used, the DNA purification methods may vary within the framework of standard operating procedures 25 depending on the individual production line, but the known approaches to scaling, industrial production and purification of DNA vectors using Escherichia coli strain J M 110-N AS / G DTT 1.8NAS12-IFNB1, or Escherichia coli strain JM110-NAS / GDTT1.8NAS12-IFNA14, or Escherichia coli strain JM110-NAS / GDTT1.8NAS12-IFNA2, or Escherichia coli strain JM1 10-NAS / GDTT1.8NAS12-IL12A, or Escherichia coli strain JM1 10-NAS / GDTT1.8NAS12-IL12A, or Escherichia coli strain JM1 10-NAS / GDTT1.8NAS12-IL12A, or Escherichia coli strain JM1 10-NAS / GDTT1.8NAS12-IL12A
- DNA vector GDTT1 .8NAS12-IFNB1 was constructed by cloning the 564 bp IFNB1 gene coding region. into the DNA vector GDTT1.8NAS12 with a size of 2591 bp. the restriction sites BamHI and Sal.
- the 564 bp coding part of the IFNB1 gene. was obtained by isolating total RNA from a biological sample of human tissue, followed by a reverse transcription reaction using a commercial kit Mint-2 (Evrogen, Russia) and PCR amplification using oligonucleotides:
- the gene therapy DNA vector GDTT1.8NAS12 was constructed by combining six DNA fragments obtained from different sources:
- the hGH-TA transcription terminator was obtained by PCR amplification of a region of human genomic DNA using the hGH-F and hGH-R oligonucleotides (sequence listing, (3) and (4));
- a kanamycin resistance gene was obtained by PCR amplification of a portion of the commercial human plasmid pET-28 using oligonucleotides Kan-F and Kan-R (sequence listing, (10) and (11));
- a polylinker was obtained by kininating and annealing four synthetic oligonucleotides MCS1, MCS2, MCS3 and MCS4 (sequence listing, (12) - (15));
- PCR amplification was performed using a commercial Phusion® High-Fidelity DNA Polymerase kit (New England Biolabs) according to the manufacturer's instructions. Fragments (a), (b), (c), and (d) had overlapping regions for the possibility of combining them with subsequent PCR amplification. Fragments (a), (b), (c) and (d) were combined using the hGH-F and Kan-R oligonucleotides (sequence listing, (3) and (11)). Further, the obtained DNA fragments were combined by restriction, followed by ligation at the BamHI and NcoI sites. As a result, a vector was obtained that does not yet contain a polylinker.
- the plasmid was cleaved with restriction endonucleases at the BamHI and EcoRI sites, followed by ligation with the fragment (e).
- an intermediate vector of 2408 bp was obtained, carrying the kanamycin resistance gene, which does not yet contain the promoter-regulatory region of the gene for the elongation factor EF1a with its own enhancer.
- the resulting vector was digested with restriction endonucleases at the Sail and BamHI sites, followed by ligation with fragment (e).
- a vector of 3608 bp was obtained, carrying the kanamycin resistance gene and the promoter-regulatory region of the gene for the elongation factor EF1a with its own enhancer. Further, the kanamycin resistance gene was isolated at the sites restriction Spel, after which the remaining fragment was ligated to itself.
- a gene therapeutic DNA vector GDTT1.8NAS12 with a size of 2591 bp was obtained, which is recombinant, with the possibility of selection without antibiotics.
- Cleavage of the amplification product of the coding portion of the IFNB1 gene and the GDTT1.8NAS12 DNA vector was performed with restriction endonucleases BamHI and Sail (New England Biolabs, USA).
- GDTT1.8NAS12-IFNA14 carrying the target gene, namely the IFNA14 gene.
- Gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 was constructed by cloning the 570 bp coding part of the IFNA14 gene. into the DNA vector GDTT1.8NAS12 with a size of 2591 bp. by restriction sites BamHI and Sail.
- the coding part of the IFNA14 gene is 570 bp. was obtained by isolating total RNA from a biological sample of human tissue, followed by a reverse transcription reaction using a commercial kit Mint-2 (Evrogen, Russia) and PCR amplification using oligonucleotides: IFNA14-FW
- IFNA14 with a size of 3126 bp. with the nucleotide sequence SEQ ID NO Q 2 AND the general structure depicted in FIG. 1B.
- the gene therapy DNA vector is GDTT1.8NAS12 was constructed according to Example 1.
- IFNA2 was constructed by cloning the 567 bp coding portion of the IFNA2 gene. into the DNA vector GDTT1.8NAS12 with a size of 2591 bp. by restriction sites BamHI and Sail.
- the 567 bp coding part of the IFNA2 gene. obtained 25 by isolating total RNA from a biological sample of human tissue, followed by a reverse transcription reaction using a commercial kit Mint-2 (Evrogen, Russia) and PCR amplification using oligonucleotides:
- the gene therapy DNA vector GDTT1.8NAS12 was constructed according to Example 1.
- GDTT1.8NAS12-IL12A carrying the target gene, namely the IL12A gene.
- the gene therapy DNA vector GDTT1.8NAS12-IL12A was constructed by cloning the 762 bp coding portion of the IL12A gene 25. into the DNA vector GDTT1.8NAS12 with a size of 2591 bp. by restriction sites Sail and Kpnl.
- the 762 bp coding part of the IL12A gene obtained by isolating total RNA from a biological sample human tissue followed by a reverse transcription reaction using a commercial kit Mint-2 (Evrogen) and PCR amplification using oligonucleotides: IL12A-up
- the gene therapy DNA vector GDTT1.8NAS12 was constructed according to Example 1.
- the gene therapy DNA vector GDTT1.8NAS12-IL12B was constructed by cloning the 987 bp coding region of the IL12B gene. into the DNA vector GDTT1.8NAS12 with a size of 2591 bp. by restriction sites Sail and Kpnl.
- the coding part of the IL12B gene is 987 bp. was obtained by isolating total RNA from a biological sample of human tissue, followed by a reverse transcription reaction using a commercial 5 kit Mint-2 (Evrogen) and PCR amplification using oligonucleotides:
- the gene therapy DNA vector GDTT1.8NAS12 was constructed according to Example 1.
- test tube N ° 2 1 ⁇ l of solution was added to 25 ⁇ l of Opti-MEM medium (Gibco, USA) Lipofectamin 3000. Mix gently with gentle shaking. The contents of tube N ° 1 were added to the contents of tube N22, incubated for 5 min at room temperature. The resulting solution was added dropwise 5 to the cells in a volume of 40 ⁇ l.
- Opti-MEM medium Gibco, USA
- RNA from a primary culture of human lung fibroblast cells was isolated using Trizol Reagent (Invitrogen, USA) according to the manufacturer's recommendations. 1 ml of Trizol Reagent was added to a well with cells and homogenized, followed by heating for 5 min at 65 ° ⁇ .
- the sample was centrifuged at 14000g for 10 min and again heated for 10 min at 65 ° C. Then, 200 ⁇ L of chloroform was added, smoothly mixed, and centrifuged at 14,000 g for 10 min. Then the aqueous phase was taken, 1/10 volume of 3M sodium acetate, pH 5.2, and an equal volume of isopropyl alcohol were added to 25 of it. The sample was incubated at -20 ° C for 10 min, followed by centrifugation at 14,000g for 10 min. The precipitate was washed with 1 ml of 70% ethanol, dried in air, and dissolved in 10 ⁇ L of RNase-free water.
- oligonucleotides were used:
- the reaction was carried out on a CFX96 amplifier (Bio-Rad, USA) under the following conditions: 1 cycle of reverse transcription at 42 ° C for 30 minutes, denaturation at 98 ° C for 15 min, then 40 cycles including denaturation at 94 ° C for 15 sec, annealing primers 60 ° ⁇ - 30 sec and elongation 72 ° ⁇ - 30 sec.
- the B2M gene (Beta-2 microglobulin) listed in the GenBank database under the number NM 004048.2 was used as a reference gene.
- amplicons obtained by PCR on templates which are plasmids in known concentrations containing cDNA sequences genes IFNB1 and B2M.
- Deionized water was used as a negative control.
- the dynamics of accumulation of cDNA amplicons of the IFNB1 and B2M genes was assessed in real time using the Bio-RadCFXManager 2.1 thermocycler software (Bio-Rad, USA). The analysis plots are shown in FIG. 2.
- SK-LU-1 human lung adenocarcinoma cells were cultured in DMEM (GIBCO) medium supplemented with 10% bovine embryo serum under standard conditions (37 ° C, 5% CO2). To obtain 90% confluence, 24 hours prior to transfection, cells were seeded in a 24-well plate at 5x10 4 cells / well. The Lipofectamine 3000 reagent (ThermoFisher is Scientific, USA) was used for transfection. Transfection with the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 expressing the human IFNA14 gene was performed as described in Example 6. The B2M gene (Beta-2 microglobulin) listed in the GenBank database under the number NM 004048.2 was used as a reference gene.
- RNA isolation, reverse transcription reaction and real-time PCR were performed as described in example 6, with the exception of oligonucleotides with sequences differing from example 6.
- oligonucleotides IFN14_SF GGC AACC AGTT CC AG AAAGC 5 IFN14_SR C AC AC AGGCTT CC AGGT CAT were used, the length of the amplification product was 168 bp.
- DNA vector GDTT1.8NAS12-IFNA2 carrying the target gene penetrate into eukaryotic cells and confirm its functional activity at the level of mRNA expression of the target gene.
- This example also demonstrates the feasibility of a method for using a gene therapy DNA vector carrying the target gene.
- a culture of BZR human bronchial epithelium cells was grown using a BEGM Kit (Lonza, Catalog No. CC-3170) under standard conditions (37 ° C, 5% CO2). To obtain 90% confluence, 24 hours prior to transfection, cells were seeded in a 24-well plate at 5x10 4 cells / well. Lipofectamine 3000 reagent (ThermoFisher Scientific, USA) was used for transfection. Transfection with the gene therapy DNA vector GDTT1.8NAS12-IFNA2 expressing the human IFNA2 gene was performed as described in Example 6.
- B The B2M gene (Beta-2-microglobulin) listed in the GenBank database under the number NM 004048.2 was used as a reference gene.
- a culture of BZR human bronchial epithelium cells transfected with the gene therapeutic DNA vector GDTT1.8NAS12, which does not carry the target gene (cDNA of the IFNA2 gene before and after transfection with the gene therapeutic DNA vector GDTT1.8NAS12, which does not contain the insert of the target gene, is not shown in the figures) was used as a control.
- Isolation of RNA, reverse transcription reaction and real-time PCR were performed as described in example 5, except for oligonucleotides with different sequences from example 6.
- oligonucleotides IFNA2_SF AGCT G AAT G ACCT GG AAGCC were used
- a human umbilical vein endothelial cell culture HUVEC was grown using Vascular Cell Basal Medium and Endothelial Cell Growth Kit-BBE (ATCC PCS-1 00-040) under standard conditions (37 ° C, 5% CO2). To obtain 90% confluence, 24 hours prior to transfection, cells were seeded in a 24-well plate at 5x10 4 cells / well. Lipofectamine 3000 reagent (ThermoFisher Scientific, USA) was used for transfection. Transfection with the gene therapeutic DNA vector GDTT1.8NAS12-IL12A expressing the human IL12A gene was performed as described in Example 6.
- the B2M gene (Beta-2-microglobulin) listed in the GenBank database under the number NM 004048.2 was used as a reference gene. Deionized water was used as a negative control.
- the amount of PCR products - cDNA of the IL12A and B2M genes obtained as a result of amplification was estimated in real time using the software of the Bio-RadCFXManager 2.1 amplifier (Bio-Rad, USA).
- the analysis plots are shown in FIG. 5. From figure 5 it follows that as a result of transfection of the human umbilical vein endothelial cell culture HUVEC with the gene therapeutic DNA vector GDTT1.8NAS12-IL12A, the level of specific mRNA of the human IL12A gene increased many times, which confirms the ability of the vector to penetrate into eukaryotic cells and express the IL12A gene on mRNA level.
- the presented results also confirm the feasibility of the method of using the gene therapeutic DNA vector GDTT1.8NAS12-IL12A to increase the expression level of the IL12A gene in eukaryotic cells.
- Example 10 Confirmation of the ability of the gene therapy DNA vector GDTT1.8NAS12-IL12B carrying the target gene, namely, the IL12B gene, to penetrate into eukaryotic cells and confirmation of its functional activity at the level of mRNA expression of the target gene.
- This example also demonstrates the feasibility of a method for using a gene therapy DNA vector carrying the target gene.
- Changes in the accumulation of mRNA of the target IL12B gene in the HSkM human skeletal myoblast cell culture were evaluated 48 hours after their transfection with the gene therapeutic DNA vector GDTT1.8NAS12-IL12B carrying the human IL12B gene.
- the amount of mRNA was determined by the dynamics of accumulation of cDNA amplicons in the real-time PCR reaction.
- Human skeletal myoblast cells HSkM were grown according to the manufacturer's instructions under standard conditions (37 ° C, 5% CO2). To obtain 90% confluence, 24 hours prior to transfection, cells were seeded in a 24-well plate at 5x10 4 cells / well.
- Lipofectamine 3000 reagent (ThermoFisher Scientific, USA) was used for transfection. Transfection with the gene therapeutic DNA vector GDTT1.8NAS12-IL12B expressing the human IL12B gene was performed as described in Example 6. As a control, we used a culture of HSkM human skeletal myoblasts cells transfected with the gene therapeutic DNA vector GDTT1.8NAS12, which does not carry the target gene (cDNA of the gene IL12B before and after transfection gene therapy DNA vector GDTT1.8NAS12, not containing the insert of the target gene is not shown in the figures). Isolation of RNA, reverse transcription reaction and real-time PCR were performed as described in example 6, with the exception of oligonucleotides with different sequences from example 6. Oligonucleotides were used to amplify DNA specific for the human IL12B gene.
- Human lung fibroblast cell culture was grown as described in example 6.
- the DN1K / dendrimer complex was prepared according to the manufacturer's method (QIAGEN, SuperFect Transfection Reagent Flandbook, 2002) with some modifications.
- culture medium was added to 1 ⁇ g of flFIK vector dissolved in TE buffer to a final volume of 60 ⁇ l, then 5 ⁇ l SuperFect Transfection Reagent was added and gently mixed by pipetting five times.
- the complex was incubated at room temperature for 10-15 minutes. Next, the culture medium was taken from the wells, the wells were washed with 1 ml of PBS buffer.
- the medium was carefully removed, the cell monolayer was washed with 1 ml of PBS buffer. Then added a medium containing 10 ⁇ g / ml gentamicin, and incubated for 24-48 hours at 37 ° C in an atmosphere of 5% CO2.
- IFNB1 protein was performed by enzyme-linked immunosorbent assay (ELISA) using the Human IFN-b (Interferon Beta) ELISA Kit (ElabBioscience E-EL-H0085) according to the manufacturer's procedure with optical density detection 5 using an automatic biochemical and enzyme-linked immunosorbent assay ChemWell (Awareness Technology Inc., USA).
- ELISA enzyme-linked immunosorbent assay
- the numerical value of the concentration was determined using a calibration curve constructed from 10 standard samples with a known concentration of IFNB1 protein included in the kit.
- the sensitivity of the method was at least 18.75 pg / ml, the measurement range was from 31.25 pg / ml to 2000 pg / ml.
- Statistical processing of the results was carried out using is software for statistical processing and data visualization R, version 3.0.2 (https: //www.r-project.org/). The plots obtained as a result of the analysis are presented in FIG. 7.
- Example 12 Confirmation of the efficiency and feasibility of the method of using the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 carrying the IFNA14 gene to increase the expression of the IFNA14 protein in mammalian cells.
- the change in the amount of protein in the culture of human lung adenocarcinoma cells SK-LU-1 (ATCC ® ⁇ -57 TM ) after transfection of these cells with the DNA vector GDTT1.8NAS12-IFNA14 carrying the human IFNA14 gene was evaluated.
- the cells were grown as described in example 7.
- SuperFect reagent was used for transfection.
- Transfection Reagent 6th generation (Qiagen, Germany).
- a control we used an aqueous solution of dendrimers without a DNA vector (A), a DNA vector GDTT1.8NAS12 that does not contain the cDNA of the IFNA14 gene (B), as transfected agents, a DNA vector GDTT1.8NAS12-IFNA14 carrying the human IFNA14 gene ( WITH).
- Preparation of the DNA-dendrimer complex and transfection of SK-LU-1 cells were performed as described in Example 11.
- 0.1 ml of 1N HCl was added to 0.5 ml of culture fluid, mixed thoroughly and incubated for 10 minutes at room temperature. Then the mixture was neutralized by adding 0.1 ml of 1.2M NaOH / 0.5M HEPES (pH 7-7.6) and mixed thoroughly. Selected the supernatant and used it to quantify the target protein.
- IFNA14 protein The quantitative determination of IFNA14 protein was carried out by the method of enzyme-linked immunosorbent assay (ELISA) using the Human IFNA14 / Interferon Alpha 14 ELISA Kit (Sandwich ELISA) (LifeSpan BioSciences LS-F13512-1) according to the manufacturer's procedure with optical density detection using an automatic biochemical and enzyme immunoassay analyzer ChemWell (Awareness Technology Inc., USA).
- ELISA enzyme-linked immunosorbent assay
- the numerical value of the concentration was determined using a calibration curve constructed from standard samples with a known concentration of IFNA14 protein included in the kit.
- the sensitivity of the method was no less than 15.6 pg / ml, the measurement range was from 15.6 pg / ml to 1000 pg / ml.
- Statistical processing of the obtained results was carried out using software for statistical processing and data visualization R, version 3.0.2 (https: //www.r-project.org/). The plots obtained as a result of the analysis are presented in FIG. eight.
- the change in the amount of IFNA2 protein in the lysate of human bronchial epithelial cells BZR after transfection of these cells with the DNA vector GDTT1.8NAS12-IFNA2 carrying the human IFNA2 gene was evaluated.
- the cells were cultured as described in example 8.
- the 6th generation SuperFect Transfection Reagent (Qiagen, Germany) was used for transfection.
- As a control we used an aqueous solution of dendrimers without a DNA vector (A), a DNA vector GDTT1.8NAS12 without cDNA of the IFNA2 gene (B), as transfected agents, a DNA vector GDTT1.8NAS12-IFNA2 carrying the human IFNA2 gene ( WITH).
- Preparation of the DNA-dendrimer complex and transfection of human bronchial epithelial cells with BZR were performed as described in example 11.
- IFNA2 protein was carried out by the method of enzyme-linked immunosorbent assay (ELISA) using the Human Interferon Alpha 2 ELISA Kit (Abeam, ab233622) according to the manufacturer's method with optical density detection using an automatic biochemical and enzyme-linked immunosorbent assay ChemWell (Awareness Technology Inc., USA).
- ELISA enzyme-linked immunosorbent assay
- the numerical value of the concentration was determined using a calibration curve constructed from standard samples with a known concentration of IFNA2 protein included in the kit.
- the sensitivity of the method was no less than 56.04 pg / ml, the measurement range was from 187.5 pg / ml to 12000 pg / ml.
- Statistical processing of the obtained results was carried out using software for statistical processing and data visualization R, version 3.0.2 (https: //www.r-project.org/). The plots obtained as a result of the analysis are presented in FIG. nine.
- the change in the amount of IL12A protein in the lysate of the human umbilical vein endothelial cell culture HUVEC after transfection of these cells with the DNA vector GDTT1.8NAS12-IL12A carrying the human IL12A gene was evaluated.
- the cells were cultured as described in example 9.
- the 6th generation SuperFect Transfection Reagent (Qiagen, Germany) was used for transfection.
- As a control we used an aqueous solution of dendrimers without a DNA vector (A), a DNA vector GDTT1.8NAS12 that does not contain the IL12A gene cDNA (B), as transfected agents, a DNA vector GDTT1.8NAS12-IL12A carrying the human IL12A gene ( WITH).
- Preparation of the DNA-dendrimer complex and transfection of HUVEC cells was performed as described in Example 11.
- 0.1 ml of 1N HCl was added to 0.5 ml of culture fluid, mixed thoroughly and incubated for 10 minutes at room temperature. Then neutralize the mixture by adding 0.1 ml of 1.2M NaOH / 0.5M HEPES (pH 7-7.6) and mix thoroughly. The supernatant was taken and used to quantify the target protein.
- the quantitative determination of the IL12A protein was carried out by the method of enzyme-linked immunosorbent assay (ELISA) using the Human IL12A / p35 ELISA Kit (Sandwich ELISA) (LifeSpan BioSciences LS-F24142-1) according to the manufacturer's procedure with optical density detection using an automatic biochemical and enzyme immunoassay analyzer ChemWell ( Awareness Technology Inc., USA).
- ELISA enzyme-linked immunosorbent assay
- the numerical value of the concentration was determined using a calibration curve constructed from standard samples with a known concentration of IL12A protein included in the kit.
- the sensitivity of the method was no less than 4.688 pg / ml, the measurement range was from 7.813 pg / ml to 500 pg / ml.
- Statistical processing of the obtained results was carried out using software for statistical processing and data visualization R, version 3.0.2 (https: //www.r-project.org/). The analysis plots are shown in FIG. ten.
- the change in the amount of IL12B protein in the lysate of the HSkM human skeletal myoblast cell culture after transfection of these cells with the GDTT1.8NAS12-IL12B DNA vector carrying the human IL12B gene was evaluated.
- the cells were cultured as described in example 10.
- the 6th generation SuperFect Transfection Reagent (Qiagen, Germany) was used for transfection.
- As a control we used an aqueous solution of dendrimers without a DNA vector (A), a DNA vector GDTT1.8NAS12 that does not contain the cDNA of the IL12B gene (B), and as transfected agents, a DNA vector GDTT1.8NAS12-IL12B carrying the human IL12B gene ( WITH).
- Preparation of the DNA-dendrimer complex and transfection of HSkM cells was performed as described in Example 11.
- 0.1 ml of 1N HCl was added to 0.5 ml of the culture fluid, mixed thoroughly and incubated for 10 minutes at room temperature. Then the mixture was neutralized by adding 0.1 ml of 1.2M NaOH / 0.5M HEPES (pH 7-7.6) and mixed thoroughly. The supernatant was taken and used to quantify the target protein.
- the IL12B protein was quantified by enzyme-linked immunosorbent assay (ELISA) using the Human IL12B / IL12 p40 ELISA Kit (Sandwich ELISA) (LifeSpan BioSciences LS-F24549-1) according to the manufacturer's procedure with optical density detection using an automatic biochemical and enzyme immunoassay analyzer ChemWell (Awareness Technology Inc., USA).
- ELISA enzyme-linked immunosorbent assay
- the numerical value of the concentration was determined using a calibration curve constructed from standard samples with a known concentration of IL12B protein included in the kit.
- the sensitivity of the method was at least 2 pg / ml, the measurement range was from 31.2 pg / ml to 2000 pg / ml.
- Statistical processing of the results was carried out using software for statistical processing and data visualization R, version 3.0.2 (https://www.r-project.org/). The analysis plots are shown in FIG. eleven.
- the changes in the amount of IL12A protein in human skin were assessed when the gene therapeutic DNA vector GDTT1.8NAS12-IL12A was introduced into human skin. carrying the human gene IL12A.
- three patients were injected into the skin of the forearm with the gene therapeutic DNA vector GDTT1.8NAS12-IL12A carrying the IL12A gene and in parallel were injected with placebo, which was a gene therapeutic DNA vector GDTT1.8NAS12, which did not contain the cDNA of the IL12A gene.
- the gene therapy DNA vector GDTT1.8NAS12 (placebo) and the gene therapy DNA vector GDTT1.8NAS12-IL12A carrying the IL12A gene were injected in an amount of 1 mg for each genetic construct by the tunnel method with a 30G needle to a depth of 3 mm.
- the volume of the injected solution of the gene therapy DNA vector GDTT1.8NAS12 (placebo) and the gene therapy DNA vector GDTT1.8NAS12-IL12A carrying the IL12A gene is 0.3 ml for each genetic construct.
- the foci of injection of each genetic construct were located on the forearm at a distance of 8-10 cm from each other.
- Biopsy samples were taken on the 2nd day after the introduction of genetic constructs of gene therapy DNA vectors. Biopsies were taken from the skin areas of patients in the area of injection of the gene therapy DNA vector GDTT1.8NAS12-IL12A carrying the IL12A (I) gene, gene therapy DNA vector GDTT1.8NAS12
- the skin of patients in the biopsy sampling area was preliminarily washed with sterile saline and anesthetized with lidocaine solution.
- the biopsy sample size was about 10 cubic meters. mm, weight - about 11 mg.
- the sample was placed in a buffer solution containing 50 mM Tris-HCl pH 7.6, 100 mM NaCl, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride, and homogenized until a homogeneous suspension was obtained.
- the resulting suspension was centrifuged for 10 min at 14000 g.
- the supernatant was taken and used for the quantitative determination of the target protein by enzyme-linked immunosorbent assay (ELISA).
- ELISA enzyme-linked immunosorbent assay
- the numerical value of the concentration was determined using a calibration curve constructed from standard samples with a known concentration of IL12A protein included in the kit.
- Statistical processing of the obtained results was carried out using software for statistical processing and data visualization R, version 3.0.2 (https://www.r-project.org/). according to the manufacturer's method with optical density detection using an automatic biochemical and enzyme immunoassay analyzer ChemWell (Awareness Technology Inc., USA). The analysis plots are shown in FIG. 12.
- the change in the amount of IFNA2 protein in human muscle tissue was assessed upon the introduction of the gene therapeutic DNA vector GDTT1.8NAS12-IFNA2 carrying the target gene, namely, human IFNA2 gene.
- IFNA2 In order to analyze the change in the amount of IFNA2 protein, three patients were injected into the gastrocnemius muscle tissue with a gene therapeutic DNA vector GDTT1.8NAS12-IFNA2 carrying the IFNA2 gene with a transport molecule, and in parallel, a placebo was injected, which is a gene therapeutic DNA vector GDTT1.8NAS12, which does not contain the cDNA of the gene IFNA2 with a transport molecule.
- the gene therapy DNA vector GDTT1.8NAS12 (placebo) and the gene therapy DNA vector GDTT1.8NAS12-IFNA2 carrying the IFNA2 gene were injected in an amount of 1 mg for each genetic construct by the tunnel method with a 30G needle to a depth of about 10 mm.
- the volume of the injected solution of the gene therapy DNA vector GDTT1.8NAS12 (placebo) and the gene therapy DNA vector GDTT1.8NAS12-IFNA2 carrying the IFNA2 gene is 0.3 ml for each genetic construct.
- the foci of injection of each genetic construct were located medially at a distance of 8-10 cm from each other. Biopsy samples were taken on the 2nd day after the introduction of genetic constructs of gene therapy DNA vectors.
- Biopsies were taken from areas of muscle tissue of patients in the injection zone gene therapy DNA vector GDTT1.8NAS12-IFNA2 carrying the IFNA2 gene (I), gene therapy DNA vector GDTT1.8NAS12 (placebo) (II), as well as from an intact part of the gastrocnemius muscle (III) using a MAGNUM biopsy device (BARD, USA).
- the skin of patients in the biopsy sampling area was preliminarily washed with sterile saline and anesthetized with lidocaine solution.
- the biopsy sample size was about 20 cc. mm, weight - about 22 mg.
- the sample was placed in a buffer solution containing 50 mM Tris-HCl pH 7.6, 100 mM NaCl, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride, and homogenized until a homogeneous suspension was obtained.
- the resulting suspension was centrifuged for 10 min at 14000g. The supernatant was taken and used to quantify the target protein.
- the quantitative determination of the IFNA2 protein was carried out by the method of enzyme-linked immunosorbent assay as described in example 13.
- the numerical value of the concentration was determined using a calibration curve constructed from standard samples with a known concentration of IFNA2 protein included in the kit.
- Statistical processing of the obtained results was carried out using the software for statistical processing and data visualization R, version 3.0.2 (https: //www.r-proiect.ora/y
- the graphs obtained as a result of the analysis are presented in Fig. 13.
- Example 18 Confirmation of the efficiency and feasibility of the method of using the gene therapeutic DNA vector GDTT1 .8NAS12-IFNA14 carrying the IFNA14 gene to increase the expression of the IFNA14 protein in human tissues.
- the changes in the amount of IFNA14 protein in human skin were assessed when the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 was introduced into human skin. carrying the human gene IFNA14.
- Gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 which contains the cDNA of the IFNA14 gene and the gene therapeutic DNA vector GDTT1.8NAS12, used as a placebo, which does not contain the cDNA of the IFNA14 gene, each of which was dissolved in sterile water of Nuclease-Free purity.
- DNA-cGMP grade in-vivo-jetPEI complexes were prepared in accordance with the manufacturer's recommendations.
- the gene therapy DNA vector GDTT1.8NAS12 (placebo) and the gene therapy DNA vector GDTT1 .8NAS12-IFNA14 carrying the IFNA14 gene were injected in an amount of 1 mg for each genetic construct by the tunnel method with a 30G needle to a depth of 3 mm.
- the volume of the injected solution of the gene therapy DNA vector GDTT1.8NAS12 (placebo) and the gene therapy DNA vector GDTT1.8NAS12-IFNA14 carrying the IFNA14 gene is 0.3 ml for each genetic construct.
- the foci of injection of each genetic construct were located on the forearm at a distance of 8-10 cm from each other. Biopsy samples were taken on the 2nd day after the introduction of genetic constructs of gene therapy DNA vectors.
- Biopsies were taken from the skin areas of patients in the area of injection of the gene therapy DNA vector GDTT1.8NAS12-IFNA14 carrying the IFNA14 gene (I), the gene therapy DNA vector GDTT1.8NAS12 (placebo) (II), as well as from intact skin areas (III), using a device for taking a biopsy Epitheasy 3.5 (Medax SRL, Italy).
- the skin of patients in the biopsy sampling area was preliminarily washed with sterile saline and anesthetized with lidocaine solution.
- the biopsy sample size was about 10 cubic meters. mm, weight - about 11 mg.
- the sample was placed in a buffer solution containing 50 mM Tris-HCl pH 7.6, 100 mM NaCl, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride, and homogenized until a homogeneous suspension was obtained.
- the resulting suspension was centrifuged for 10 min at 14000g. The supernatant was taken and used for the quantitative determination of the target protein by enzyme-linked immunosorbent assay as described in example 12.
- the numerical value of the concentration was determined using a calibration curve constructed from standard samples with a known concentration of IFNA14 protein included in the kit. Statistical processing of the results was carried out using software for statistical processing and data visualization R, version 3.0.2 (https://www.r-project.org/). The analysis plots are shown in FIG. fourteen.
- the patient was injected into the skin of the forearm with an appropriate culture of autologous fibroblasts transfected with the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 carrying the IFNA14 gene, and in parallel a placebo was injected, which was a culture of the patient's autologous fibroblasts transfected with the gene therapeutic DNA vector GDTT1.8NAS carrying the gene IFNA14. ...
- the primary culture of human fibroblasts was isolated from biopsies of the patient's skin. Using an Epitheasy 3.5 skin biopsy device (Medax SRL, Italy), a skin biopsy sample was taken from an area protected from ultraviolet radiation, namely behind the auricle or from the lateral inner surface in the elbow joint area, about 10 sq. mm, weighing about 11 mg. The patient's skin was preliminarily washed with sterile saline and anesthetized with lidocaine solution. The cultivation of the primary cell culture was carried out at 37 ° C in an atmosphere containing 5% CO2 in DMEM medium with 10% fetal bovine serum and ampicillin 100 U / ml. Subculture of culture and change of culture medium was carried out every 2 days.
- the total duration of culture growth did not exceed 25-30 days. An aliquot containing 5x1 0 4 cells was taken from the cell culture. The patient's fibroblast culture was transfected with a gene therapy DNA vector GDTT1.8NAS12-IFNA14 carrying the IFNA14 gene or placebo - the GDTT1.8NAS12 vector, which does not carry the target IFNA14 gene.
- Transfection was carried out using a cationic polyethyleneimine polymer JETPEI (Polyplus Transfection, France) according to the manufacturer's instructions.
- the cells were cultured for 72 hours and then administered to the patient.
- the concentration of modified autologous fibroblasts in the injected suspension was approximately 5 million cells per 1 ml of suspension, the number of injected cells did not exceed 15 million.
- the foci of autologous fibroblast culture injection were located at a distance of 8-10 cm from each other.
- Biopsy samples were taken on the 4th day after administration of the culture of autologous fibroblasts transfected with the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 carrying the target gene, namely, the IFNA14 gene and placebo. Biopsies were taken from the patient's skin areas in the zone of administration of the culture of autologous fibroblasts transfected with the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14, carrying the target gene, namely the IFNA14 gene (C), cultures of autologous fibroblasts transfected with the gene therapeutic DNA vector GDTT1.8NAS12, not carrying the target IFNA14 gene (placebo) (B), as well as from intact skin areas (A), using the device for taking a biopsy Epitheasy 3.5 (Medax SRL, Italy).
- the skin in the biopsy sampling area of the patients was preliminarily washed with sterile saline and anesthetized with lidocaine solution.
- the biopsy sample size was about 10 cubic meters. mm, weight - about 11 mg.
- the sample was placed in a buffer solution containing 50 mM Tris-HCl pH 7.6, 100 mM NaCl, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride, and homogenized until a homogeneous suspension was obtained.
- the resulting suspension was centrifuged for 10 min at 14000g. The supernatant was collected and used to quantify the target protein as described in Example 12.
- FIG. 15 The analysis plots are shown in FIG. 15. From figure 15 it follows that in the patient's skin in the area of introduction of the culture of autologous fibroblasts transfected with the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 carrying the IFNA14 gene, there was an increase in the amount of IFNA14 protein in comparison with the amount of IFNA14 protein in the area of introduction of the culture of autologous fibroblasts transfected with the gene therapy DNA vector GDTT1.8NAS12, which does not carry the IFNA14 gene (placebo), which indicates the efficacy of the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14 and confirms the feasibility of the method of its use to increase the expression level of IFNA14 in human tissues, in particular, with the introduction of autologous fibroblasts transfected with the gene therapeutic DNA vector GDTT1.8NAS12-IFNA14.
- the change in the amount of proteins IFNB1, IFNA14, IFNA2, IL12A and IL12B in the area of muscle tissue was evaluated when a mixture of gene therapy vectors was combined into this area.
- the study was carried out on 3 laboratory animals - male Wistar rats of 8 months of age weighing 240-290 g.
- Transfection reagent cGMP grade in-vivo-jetPEI polyethyleneimine (Polyplus Transfection, France) was used as a transport system.
- An equimolar mixture of gene therapy DNA vectors was dissolved in sterile water of Nuclease purity grade. Free.
- DNA-cGMP grade in-vivo-jetPEI complexes were prepared in accordance with the manufacturer's recommendations.
- the volume of the intramuscularly administered solution was 0.1 ml with a total amount of DNA of 100 ⁇ g.
- the solution was injected using an insulin syringe. 2 days after the procedure, the rats were decapitated.
- Biopsy material was taken from areas of the right thigh muscle in the area of injection of a mixture of five gene therapy DNA vectors carrying genes IFNB1, IFNA14, IFNA2, IL12A, IL12B (zone I), from areas of the left muscle of the thigh in the area of introduction of gene therapy DNA vector GDTT1.8NAS12 (placebo) (zone II), as well as from areas of muscle tissue that have not undergone any manipulation (zone III).
- Example 11 Quantifying IFNB1 protein
- Example 12 Quantifying IFNA14 protein
- Example 13 Quantifying IFNA2 protein
- Example 14 quantifying IL12A protein
- example 15 quantitative determination of IL12B protein
- CPAE cells were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco) under standard conditions.
- DMEM Gibco
- fetal bovine serum Gibco
- Transfection with the gene therapeutic DNA vector GDTT1.8NAS12-IFNA2 carrying the human IFNA2 gene and the DNA vector GDTT1.8NAS12 not carrying the human IFNA2 gene (control), RNA isolation, reverse transcription reaction, PCR amplification and data analysis was performed as described in example 8
- the bovine actin (ACT) gene listed in the GenBank database under the number AH001 130.2 was used as a reference gene.
- amplicons obtained by PCR on matrices were used, which were plasmids in known concentrations containing the sequences of the IFNA2 and ACT genes.
- Deionized water was used as a negative control.
- NAS / GDTT1.8NAS12-IL12A or Escherichia coli strain JM1 10-NAS / GDTT1.8NAS12-IL12B carrying gene therapy DNA vector GDTT1.8NAS12-IFNB1, or GDTT 1.8NAS12-IFNA14, or GDTT1.8NAS12-IFNA2, or GDTT1.8NAS12-IL12A or GDTT1.8NAS12-IL12B, respectively, for its development with the possibility of selection without the use of antibiotics consists in obtaining cells of the Escherichia coli JM110-NAS strain with electroporation of these cells with the gay therapy DNA vector GDTT1.8NAS12-IFNB1, or the DNA vector GDTT1.8NAS12-IFNA14, or the DNA vector GDTT1.8NAS12-IFNA2, or the DNA vector GDTT1.8NAS IL12A, or DNA vector GDTT1 .8NAS12-IL12B, after which the cells are plated on Petri dishes with agar selective medium containing yeast extract, peptone, 6% sucrose,
- the Escherichia coli JM110-NAS strain for the development of the gene therapeutic DNA vector GDTT1.8NAS12 or gene therapy DNA vectors based on it with the possibility of positive selection without the use of antibiotics was obtained by constructing a linear DNA fragment containing the regulatory element RNA-in of the transposon TnU for selection without the use of antibiotics 64 bp in size, the sacB levansacharase gene, the product of which provides selection on a sucrose-containing medium with a size of 1422 bp, the chloramphenicol resistance gene catR, which is necessary for the selection of strain clones in which homologous recombination of 763 bp underwent. n.
- GDTT1.8NAS12-IFNB1 SEQ ID N ° 1
- GDTT1.8NAS12-IFNA14 SEQ ID N ° 2
- GDTT1.8NAS12-IFNA2 SEQ ID N23
- GDTT1.8NAS12-IL12A SEQ ID N24
- GDTT1.8NAS12-IL12B SEQ ID N ° 5
- NAS / GDTT1.8NAS12-IL12B each containing gene therapy DNA vector GDTT1.8NAS12 carrying the target gene, namely IFNB1, or IFNA14, or IFNA2, or IL12A, or IL12B.
- Each strain of Escherichia coli JM110- NAS / GDTT1.8NAS12-IFNB1, or Escherichia coli JM110- NAS / GDTT1 .8NAS12-IFNA14, or Escherichia coli JM110- NAS / GDTT1.8NAS12-IFNA2, or Escherichia NAST1 / 8NAS12-IFNA2, or Escherichia coli -IL12A, or Escherichia coli JM110-NAS / GDTT1.8NAS12-IL12B was obtained on the basis of the Escherichia coli JM110-NAS strain (Genetic Diagnostics and Therapy 21 Ltd, UK) according to example 22 by electroporation of competent cells of this strain with the gene
- a medium was prepared containing 10 L: 100 g tryptone, 50 g yeast extract (Becton Dickinson, USA), made up to 8800 ml with water and autoclaved at 121 ° C for 20 min, then 1200 ml of 50% (w / v) sucrose was added. Then, a seed culture of the Escherichia coli strain JM110-NAS / GDTT1.8NAS12-IFNB1 in a volume of 100 ml was inoculated into a flask. Incubated in an incubator shaker for 16 h at 30 ° C.
- the seed culture was transferred to a Techfors S fermenter (Infors HT, Switzerland), grown until the stationary phase was reached.
- the control was carried out by measuring the optical density of the culture at a wavelength of 600 nm.
- the cells were precipitated by centrifugation for 30 min at 5000-10,000 days. The supernatant was removed, the cell mass was resuspended in 10% by volume of phosphate-buffered saline. They were re-centrifuged for 30 min at 5000-1 OOOOd.
- the solution was centrifuged for 20-30 min at 15000 g, then filtered through a membrane filter with pores of 0.45 ⁇ m (Millipore, USA). Then ultrafiltration was carried out through a membrane with a cutoff size of YOkDa (Millipore, United States) and diluted to the initial volume with 25 mM TrisCI buffer, pH 7.0. The operation was repeated three to four times. The solution was applied to a column with 250 ml DEAE sepharose HP sorbent (GE, USA) equilibrated with a solution of 25 mM TrisCI, pH 7.0.
- the column was washed with three volumes of the same solution, and then the gene therapy DNA vector GDTT1.8NAS12-IFNB1 was eluted with a linear gradient from a solution of 25 mM TrisCI, pH 7.0 to a solution of 25 mM TrisCI, pH 7.0, 1M NaCI in a volume of five column volumes. ... Elution was monitored by the optical density of the descending solution at 260 nm. Chromatographic fractions containing the gene therapeutic DNA vector GDTT1.8NAS12-IFNB1 were pooled and gel filtration was performed on a Superdex 200 sorbent (GE, USA). The column was equilibrated with PBS.
- the reproducibility of the technical process and the quantitative characteristics of the final product yield confirm the manufacturability and the possibility of industrial production of the gene therapeutic DNA vector GDTT1.8NAS12-IFNB1, or GDTT 1.8NAS12-IFNA14, or GDTT1.8NAS12-IFNA2, or GDTT1.8NAS12-IL12A, or is GDTT1.8NAS12-IL12B.
- the created gene therapeutic DNA vector with the target gene can be used for introduction into the cells of the body of animals and humans, characterized by reduced or insufficient expression of the protein encoded by this gene, thus ensuring the achievement of a therapeutic effect.
- the problem posed in this invention is solved, namely: the design of gene therapy DNA vectors to increase the expression level of genes IFNB1, 25 IFNA14, IFNA2, IL12A, IL12B, combining the following properties:
- DNA vectors of regulatory elements which are nucleotide sequences of viral genomes and antibiotic resistance genes; III) Manufacturability of obtaining and the possibility of production in strains on an industrial scale;
- Escherichia coli JM110-NAS / GDTT1.8NAS12-IL12B carrying a gene therapy DNA vector carrying a gene therapy DNA vector, a method for producing a gene therapy DNA vector, a method for industrial-scale production of a gene therapy DNA vector.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019144190 | 2019-12-26 | ||
RU2019144190A RU2741570C1 (ru) | 2019-12-26 | 2019-12-26 | Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, несущий целевой ген, выбранный из группы генов IFNB1, IFNA14, IFNA2, IL12A, IL12B для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNB1, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNA14, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNA2, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL12A, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL12B, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021167497A1 true WO2021167497A1 (ru) | 2021-08-26 |
Family
ID=74213122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2021/000073 WO2021167497A1 (ru) | 2019-12-26 | 2021-02-20 | Генотерапевтический днк-вектор |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2741570C1 (ru) |
WO (1) | WO2021167497A1 (ru) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4808523A (en) * | 1984-11-07 | 1989-02-28 | Yeda Research And Development Co., Ltd. | Constitutive production of human IFN-β1 by mammalian cells transformed by the IFN-β1 gene fused to an SV40 early promoter |
CN101304758B (zh) * | 2005-06-29 | 2013-08-21 | 维兹曼科学研究所耶达研究与发展有限公司 | 重组干扰素α2(IFNα2)突变体 |
RU2678756C1 (ru) * | 2017-08-25 | 2019-01-31 | Селл энд Джин Терапи Лтд | Генотерапевтический ДНК-вектор VTvaf17, способ его получения, штамм Escherichia coli SCS110-AF, способ его получения, штамм Escherichia coli SCS110-AF/VTvaf17, несущий генотерапевтический ДНК-вектор VTvaf17, способ его получения |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
-
2019
- 2019-12-26 RU RU2019144190A patent/RU2741570C1/ru active
-
2021
- 2021-02-20 WO PCT/RU2021/000073 patent/WO2021167497A1/ru active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4808523A (en) * | 1984-11-07 | 1989-02-28 | Yeda Research And Development Co., Ltd. | Constitutive production of human IFN-β1 by mammalian cells transformed by the IFN-β1 gene fused to an SV40 early promoter |
CN101304758B (zh) * | 2005-06-29 | 2013-08-21 | 维兹曼科学研究所耶达研究与发展有限公司 | 重组干扰素α2(IFNα2)突变体 |
RU2678756C1 (ru) * | 2017-08-25 | 2019-01-31 | Селл энд Джин Терапи Лтд | Генотерапевтический ДНК-вектор VTvaf17, способ его получения, штамм Escherichia coli SCS110-AF, способ его получения, штамм Escherichia coli SCS110-AF/VTvaf17, несущий генотерапевтический ДНК-вектор VTvaf17, способ его получения |
Also Published As
Publication number | Publication date |
---|---|
RU2741570C1 (ru) | 2021-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11305015B2 (en) | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules | |
CN114787357A (zh) | 用于编辑靶标rna的添加了功能性区域的反义型指导rna | |
CN118256490A (zh) | 一种环状rna、组合物和治疗疾病的方法 | |
Zarghampoor et al. | Improved translation efficiency of therapeutic mRNA | |
CN112481289A (zh) | 一种转录环状rna的重组核酸分子及其在蛋白表达中的应用 | |
Reyes-Sandoval et al. | CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses | |
JP2020535805A (ja) | 細胞の遺伝子修飾のための非組込みdnaベクター | |
JP6918231B2 (ja) | 遺伝子治療DNAベクターVTvaf17と生産方法;大腸菌株SCS110−AFと生産方法;遺伝子治療DNAベクターVTvaf17を保持する大腸菌株SCS110−AF/VTvaf17と生産方法 | |
KR20160104062A (ko) | 인공 핵산 분자 | |
CN108929870B (zh) | 抑制HBV的siRNA分子及其应用 | |
EP2307575B1 (en) | Unprocessed rolling circle amplification product | |
US20240307558A1 (en) | Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of KRT5, KRT14, LAMB3, and COL7A1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-KRT5, or Escherichia coli strain SCS110-AF/VTvaf17-KRT14, or Escherichia coli strain SCS110-AF/VTvaf17-LAMB3, or Escherichia coli strain SCS110-AF/VTvaf17-COL7A1 carrying the gene therapy DNA vector, m | |
WO2021206587A1 (en) | Sars-cov-2 dna vaccine based on gene therapy dna vector gdtt1.8nas12 | |
US9125845B2 (en) | DNA vaccines, uses for unprocessed rolling circle amplification product and methods for making the same | |
RU2741570C1 (ru) | Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, несущий целевой ген, выбранный из группы генов IFNB1, IFNA14, IFNA2, IL12A, IL12B для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNB1, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNA14, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNA2, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL12A, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL12B, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора | |
JP6385732B2 (ja) | 免疫応答制御剤 | |
JP2024516882A (ja) | 構築物と免疫刺激性化合物の共発現 | |
CN115998851A (zh) | 一种个体化mRNA组合物、载体、mRNA疫苗及其应用 | |
EP4123029A1 (en) | In-vitro transcript mrna and pharmaceutical composition comprising same | |
WO2020130873A1 (en) | Gene therapy dna vector vtvaf17 | |
RU2734726C1 (ru) | Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, несущий целевой ген, выбранный из группы генов DDC, IL10, IL13, IFNB1, TNFRSF4, TNFSF10, BCL2, HGF, IL2 для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli JM110-NAS/GDTT1.8NAS12-DDC, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL10, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL13, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNB1, или Escherichia coli JM110-NAS/GDTT1.8NAS12-TNFRSF4, или Escherichia coli JM110-NAS/GDTT1.8NAS12-TNFSF10, или Escherichia coli JM110-NAS/GDTT1.8NAS12-BCL2, или Escherichia coli JM110-NAS/GDTT1.8NAS12-HGF, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL2, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора | |
CN114107303A (zh) | sgRNA、质粒、IRF7功能缺失的细胞系及其构建方法和应用 | |
WO2021137742A1 (ru) | Генотерапевтический днк-вектор | |
Liu et al. | Development and application of an uncapped mRNA platform | |
US20240238407A1 (en) | Htlv-1 nucleic acid lipid particle vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21756466 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21756466 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/07/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21756466 Country of ref document: EP Kind code of ref document: A1 |